Document is current
Any future updates will be listed below
-
Authors
Wu, Yuqi
Wong, Oscar Wing Ho
Chen, Sizhe
Ng, Siew Chien
Su, Qi
Chan, Francis Ka Leung
-
Funding
Funding for this research was provided by:
InnoHK, The Government of Hong Kong, Special Administrative Region of the People’s Republic of China
Research Grants Council–Research Impact Fund (R4030-22)
New Cornerstone Science Foundation (NCI202346)
Hong Kong PhD Fellowship Scheme (HKPFS) of the Research Grants Council of Hong Kong (PF22-77807)
- License Information
-
More Information
Article History
Received: 20 May 2025
Accepted: 30 May 2025
First Online: 18 June 2025
Declarations
:
: S.C.N. has served as an advisory board member for Pfizer, Ferring, Janssen and Abbvie and received honoraria as a speaker for Ferring, Tillotts, Menarini, Janssen, Abbvie and Takeda; has received research grants through her affiliated institutions from Olympus, Ferring and Abbvie; is a founder member, non-executive director, non-executive scientific advisor and shareholder of GenieBiome Ltd which is non-remunerative; is a shareholder of MicroSigX Diagnostic Holding Limited; is a founder member, non-executive Board Director, and non-executive scientific advisor of MicroSigX Biotech Diagnostic Limited, which is non-remunerative; and receives patent royalties through her affiliated institutions. F.K.L.C. serves as the Principal Investigator for the Fecal Microbiota Transplantation Service under the Hospital Authority (HA). He is a Board Director of EHealth Plus Digital Technology Ltd., an HA-owned subsidiary driving the eHealth+ program to transform the Electronic Health Record Sharing System into a comprehensive digital healthcare platform and advance other IT initiatives within the eHealth ecosystem. In addition, he is a Board Director of CUHK Medical Services Limited. F.K.L.C. is a shareholder of GenieBiome Holdings Limited and the co-founder, non-executive Board Chairman, and non-executive Scientific Advisor of its wholly owned subsidiary, GenieBiome Ltd. Similarly, he is a shareholder of MicroSigX Diagnostic Holding Limited and the co-founder, non-executive Board Chairman, and non-executive Scientific Advisor of its wholly owned subsidiary, MicroSigX Biotech Diagnostic Limited. He also serves as a Director of the Hong Kong Investment Corporation Limited and a member of the Steering Committee for the RAISe+ Scheme under the Innovation and Technology Commission. Furthermore, he is the Co-Director of the Microbiota I-Center (MagIC) Ltd. F.K.L.C. receives advisory fees and speaker honoraria from AstraZeneca and Comvita New Zealand Limited, as well as patent royalties through affiliated institutions for microbiome-related applications.
